AbbVie completes acquisition of Apogee Therapeutics for USD 10.9 billion

PUBT · 1d ago
AbbVie completes acquisition of Apogee Therapeutics for USD 10.9 billion
  • AbbVie completed its acquisition of Apogee Therapeutics, paying USD 135.11 per share in cash for about USD 10.9 billion.
  • Apogee shareholders were cashed out; the stock stopped trading on Nasdaq before the market opened on Sept. 3, 2026.
  • Deal adds immunology pipeline assets led by IL-13 antibody zumilokibart for atopic dermatitis, with longer-acting dosing under evaluation.
  • AbbVie expects a USD 0.14 hit to 2026 adjusted diluted EPS, about USD 0.46 in 2027; accretion forecast from 2032.
  • 2026 adjusted diluted EPS guidance reaffirmed at USD 13.87 to USD 14.07, including the acquisition’s partial-year dilution.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609030834PR_NEWS_USPR_____CG39902) on September 03, 2026, and is solely responsible for the information contained therein.